$DRMA

Dermata Therapeutics, Inc. (DRMA) filed an SEC Form 8-K — Other Events. Item 8.01. Other Events. On October 29, 2027, Dermata Therapeutics, Inc. (the “Company”) issued a press release announcing enrollment of the first participant in a clinical trial evaluating Tome Clearing Treatment, the Company’s once-weekly acne treatment, in participants with ac

Dermata Therapeutics (DRMA) has started a clinical trial for its once-weekly acne treatment, Tome Clearing Treatment, aiming for a H1 2027 launch. The trial will evaluate the treatment's effectiveness in reducing acne lesions and hyperpigmentation. The company expects this to be its second commercial product, following Tome Foundational Treatment. According to Dermata, acne affects 50 million Americans annually, presenting a significant market opportunity.

Dermata Therapeutics reported positive results from a cosmetic study of its Tome treatment, with 71% of participants showing improvement after one use. The company cited investigator-graded enhancements after four treatments. This supports Dermata's shift to commercial skincare, though further studies and sales data are needed for stronger validation, according to the company.

Modular Medical (MODD) rose 13.48% in overnight trading after a 23.37% drop earlier, planning a 2026 launch for its Pivot tubeless patch pump. Jin Medical (ZJYL) gained 20.79% with no specific news. InnovAge (INNV) increased 9.51% after reporting a 15.9% revenue rise. Pyxis Oncology (PYXS) climbed 5% ahead of a key clinical update. Pulse Biosciences (PLSE) fell 2.48% despite clinical trial progress. Dermata (DRMA) rose 7.20% after launching its Tome skincare brand. Dogwood Therapeutics (DWTX) ga

Dermata Therapeutics (DRMA) launched its Tome Foundational Treatment, a once-weekly skincare product powered by Bioneedle. The treatment is available for purchase or subscription at www.tomeskincare.com. The company aims to expand its Tome skincare portfolio and drive consumer adoption.

Dermata Therapeutics (NASDAQ:DRMA) announced preorders for its Tome Foundational Treatment, a once-weekly topical mask, are open ahead of its August 25, 2026 commercial launch. The treatment retails at $178, with subscribers receiving a 10% discount. The company aims to fill a gap in the skincare market with a natural, professional-grade product.

Dermata Therapeutics, Inc. (DRMA) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Dermata Therapeutics Announces $3.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules $3.4 million upfront with up to approximately $6.7 million of potential additional gross proceeds upon the exercise in full of warrants SAN DIEGO, CA / ACCESSWIRE /

Dermata Therapeutics (DRMA) reported Q2 2026 results for the quarter ended June 30, 2026, with a net loss of $2.97 million, or $0.74 per diluted share, versus $1.70 million in Q2 2025. Operating expenses rose to $3.0 million. Cash was $4.4 million, expected to fund operations into Q4 2026. The company plans to launch Tome Foundational Treatment Aug. 25, 2026.

Dermata Therapeutics (NASDAQ:DRMA) reported Q2 2026 results and corporate updates. The company said its first commercial product, Tome Foundational Treatment, is expected to launch and begin selling on Aug. 25, 2026, with a second weekly OTC acne product planned later. Cash fell to $4.4M at June 30, 2026 from $7.5M at Dec. 31, 2025.

Dermata Therapeutics, Inc. (DRMA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Second Quarter 2026 - Dermata announced the launch date of its first commercial product, Tome™ Foundational Treatment, expected on August 25, 2026 – - Dermata recently attended Be+We